Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma

Biomarker Research

Table 1 Different PI3K pathway inhibitors in NHL

Inhibitors	Targets	Lymphoma type	References
NVP-BEZ235	Dual PI3K and mTOR	FL, DLBCL, MCL,T-ALL	[14–17]
CAL-101	Isoform-specific PI3K(δ)	CLL, MCL	[18, 19]
NVP-BKM120	Pan-isoform PI3K	B-CLL, DLBCL	[20, 21]
LY294002	Pan-isoform PI3K	DLBCL, MCL, BL, T-ALL	[22–25]
GDC-0941	Pan-isoform PI3K	MCL, T-cell lymphoma	[26, 27]
RAD001	mTOR	MCL	[28]
PI-103	Dual PI3K and mTOR	BL, T-ALL	[25, 29]

ISSN: 2050-7771